TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00644241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell harvest
Description: stem cells will be harvested from the iliac crest of the patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angiographic transplantation of stem cells
Description: autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
Study: NCT02325804

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Counseling
Description: In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
Study: NCT03726541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
Study: NCT01193049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets as a single oral dose on Day 1 of each study period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets as a single oral dose on Day 1 of each study period
Study: NCT03535090

Intervention type: DRUG
Intervention: Methylprednisolone
Study: NCT02126527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auranofin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study: NCT02998528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Specified dose on specified days
Study: NCT02126527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00910936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 weeks endurance training, 3 times weekly for 35 minutes
Study: NCT04146402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A+chemo
Description: SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos+chemo
Description: Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
Study: NCT02998528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Specified dose on specified days
Study: NCT02829606

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: small scotoma using Head Mounted Display No re-mapping
Description: re-mapping software turned off

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: small scotoma using Head Mounted Display No re-mapping
Description: re-mapping software turned off

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large scotoma using Head Mounted Display PLUS re-mapping
Description: re-mapping software turned on

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Large scotoma using Head Mounted Display PLUS re-mapping
Description: re-mapping software turned on
Study: NCT01779895

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei probiotic strain

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: maltodextrin
Study: NCT04483752

Intervention type: OTHER
Group type: OTHER
Intervention: CHEST CT SCAN
Description: Chest CTscan at 3 and 12 months
Study: NCT00887068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
Study: NCT02998528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study: NCT02092324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study: NCT02977533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZ402668
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02933372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.
Study: NCT02221960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6383
Description: Subjects will receive MEDI6383 until disease progression or adverse event.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6383 and MEDI4736
Description: Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
Study: NCT01945788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide (rDNA origin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (rDNA origin)
Study: NCT01063946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombrabulin (AVE8062)
Description: Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion
Study: NCT02863861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol-ketamine
Study: NCT01372813

Intervention type: DRUG
Group type: OTHER
Intervention: vandetanib
Description: Daily dose 300mg/day by mouth, 28 day cycle
Study: NCT01406158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate Formulation A
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate Formulation B
Description: oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: oral tablet
Study: NCT02451254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: circumferential ablation
Description: circumferential ablation of the pulmonary veins

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SVT ablation
Description: SVT ablation
Study: NCT00910013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.5% intra-articular ropivacaïne (20cc)
Study: NCT03696004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-100
Description: Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-100
Description: Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
Study: NCT02998528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: This arm is closed and no longer enrolling patients.
Study: NCT04374136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL001
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intravenous (IV) infusion
Study: NCT01470495

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: treat Recurrent HCC with RFA
Study: NCT00470067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: IV
Study: NCT02576912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) given intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pregnenolone
Description: A dose given sublingually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Pregnenolone
Description: A dose given sublingually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo dose given sublingually.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo dose given sublingually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose given intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose given intravenously.
Study: NCT03402750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meds to Beds
Description: Medications will be delivered to patient bedside before discharge

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Prescription
Description: Patient or surrogate can pick up medication from pharmacy
Study: NCT03735069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPT (Indirect pulp treatment)
Description: Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cvek/partial pulpotomy
Description: Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical pulpotomy
Description: Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
Study: NCT00005983

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: surgery
Study: NCT04285593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bulgarian squats
Description: The intervention using Bulgarian squat exercises will consist in the application of the protocol described by Aguilera-Castells et al. The technique will be done with the footballer standing. The athlete with one foot in front and the other behind the body, arms crossed over her chest, and her upper body, will remain upright with a natural swing in the lower back during the entire exercise. The players will lower the body (eccentric phase) until the front knee flexes to 90º. Subsequently, they will return to the initial position with a full extension of the knee of the front leg (concentric phase), maintaining an erect trunk position. The front foot will be placed in a fixed position contacting the ground, and the rear foot will rest on a horizontal press bench.
Study: NCT02293369

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cuff closure via vaginal route
Description: Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cuff closure via laparoscopic route
Description: Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
Study: NCT00460538

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lectranal
Description: Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
Study: NCT01104779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study: NCT02006693

Intervention type: DEVICE
Group type: OTHER
Intervention: XEN® Gel Stent
Description: The XEN® Gel Stent (XEN45 implant) was placed in the study eye.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cataract Surgery
Description: Participants diagnosed with a cataract elected to have cataract surgery.
Study: NCT01589965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive through lotteries
Description: Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive through lotteries
Description: Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
Study: NCT02125253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate Nasal Spray, 50 mcg
Description: a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex Nasal Spray, 50 mcg
Description: a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: a metered-dose, manual pump spray unit containing an aqueous suspension
Study: NCT04668911

Intervention type: OTHER
Intervention: Swab
Description: PCR test for SARS-CoV2, oral and nasal swab

Intervention type: OTHER
Intervention: Swab
Description: PCR test for SARS-CoV2, oral and nasal swab

Intervention type: OTHER
Intervention: Swab
Description: PCR test for SARS-CoV2, oral and nasal swab
Study: NCT02504671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
Study: NCT04374136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label - AL001
Description: Administered via intravenous (IV) infusion
Study: NCT02504671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
Study: NCT04102280

Intervention type: DEVICE
Group type: OTHER
Intervention: Dialyser
Description: Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
Study: NCT04300283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: See previous description
Study: NCT02183207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy
Description: Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
Study: NCT02315196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study: NCT02002065

Intervention type: BIOLOGICAL
Intervention: Inactivated HAV vaccine
Description: Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose

Intervention type: BIOLOGICAL
Intervention: Attenuated alive HAV vaccine
Description: Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose